Webinar - 2020

PET/SPECT/CT在癌症转化研究和癌症靶向治疗中的作用

如今,非侵入性成像被广泛用于研究癌症发生和发展的复杂生物过程以及肿瘤基质的相互作用。通过将放射性同位素标记在特定的配体上再进行PET/SPECT/CT 扫描,可以明确疾病的位置,也可以确认受体的表达或涉及肿瘤及其微环境的分子通路。

研讨会简介

癌症是一种动态的疾病,在其发展过程中会出现异质性。肿瘤的异质性将导致不同的分子特征,对治疗的敏感程度也不同,这些都可以通过非侵入性的成像方式,如PET/SPECT/CT进行精确监测。这些成像结果不仅可以帮助我们更多地了解癌症本身,还可以精确地检测出肿瘤的靶点,以便进一步有效地开发药物和对病人进行分层。

在本次网络研讨会上,Pradip Chaudhari博士将深入介绍如何在动物模型中识别和定位肿瘤,通过特定的分子靶点来描述肿瘤的特征,监测肿瘤发生的复杂途径,并通过非侵入性的临床前PET/SPECT/CT图像来评估治疗效果。这些图像结果并不局限于临床前应用,而是可以进入临床,用于进一步的药物开发和病人选择。

在Gabriela Kramer-Marek博士的演讲中,她将讨论通过靶向PET放射线范围在癌症中的靶向分子图像,以准确地选择病人,了解内在的抗性机制或治疗开始后出现的获得性抗性,以及在单药治疗不够有效的情况下选择最有效的联合方案。这些工作将实现对免疫疗法的智能监测,并扩大个性化医疗方法的机会。

重点讨论内容

  • 利用PET/SPECT/CT对癌症的发生、发展和转移中错综复杂的途径过程进行可视化和定量分析
  • 无创图像在癌症转化研究和抗癌药物开发中的应用
  • 免疫PET对癌症的早期检测
  • 利用免疫PET技术评估免疫治疗的效果并探索个体化医疗

推荐参会人员

本次网络研讨会适合对非侵入性图像在转化性癌症研究、癌症免疫治疗和个性化医疗中的应用感兴趣的基础生物学家、放射化学家、临床医生和药物开发商。对免疫检查点抑制剂感兴趣的癌症生物学和免疫疗法领域的研究人员也会从本次研讨会中获益。

主讲人简介

Dr. P. R. Chaudhari

Senior Scientist, Comparative Oncology & Small Animal Imaging Facility, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai

Dr. Pradip Chaudhari obtained his post-graduate degree in Veterinary Science from Bombay Veterinary College, Mumbai. Immediately after completion of his postgraduate studies, he joined Bhabha Atomic Research Center where he worked in the field of basic and applied nuclear medicine research. He also obtained post-graduate diploma in medical radioisotopes and technology as well as doctoral degree in Applied Biology from University of Mumbai. He worked exclusively on animal model development for osteoporosis, cancer and arthritis. He has also explored application of nuclear medicine diagnostic procedures for veterinary patients that has laid a foundation of dedicated Veterinary Nuclear Medicine Centre at Bombay Veterinary College. He has played instrumental role in biological evaluation of various SPECT / PET diagnostic and therapeutic radiotracers. He has initiated a nuclear imaging for large as well as small animals. His doctoral work involving biological evaluation of therapeutic agents for rheumatoid arthritis and bone pain palliation has translated for clinical application in humans.

Dr Gabriela Kramer-Marek

Team Leader

Dr Gabriela Kramer-Marek received her Ph.D. degree in Medical Physics in 2005 from Silesian University, Poland, and the following year joined the Radiation Oncology Branch, NCI/NIH, Bethesda, USA, to work as a postdoctoral research fellow on the development and characterisation of molecular probes for in vivo detection and quantification of tumour-specific markers. In 2012 she accepted her first faculty position (Research Assistant Professor) in the Department of Medicine, at the Indiana University, Indianapolis, US. From July 2013 she has been leading the Preclinical Molecular Imaging Team at the Institute of Cancer Research in London, UK.

Registration

Input value is invalid.

Are you already in contact with your Bruker representative regarding any product inquiries?

We constantly want to improve our service for our customers. In answering the following question you help us to serve your needs even better in the future: What best describes your situation?

By ticking this box, I agree to receive, from time to time, emails from Bruker and its affiliates within the Bruker Group on upcoming events, webinars, our products and services, surveys and Bruker's corporate news.
I can unsubscribe at any time, by contacting Bruker or clicking on the opt-out link in the email if available. For more information on the processing of your personal data, please check Bruker’s Privacy Policy. 

By submitting this form I agree my personal data will be used to process my registration to the webinar. I have read and accepted the Bruker Website Privacy Notice (https://www.bruker.com/privacy-policy.html) and I agree to the Terms of Use (https://www.bruker.com/terms-of-use.html) of the Bruker website.

Already registered and lost your invitation link?

Thank you. The invitation link has been resent.